Therapeutic Nuclear Medicine Market Size, Share and Industry Analysis Report, Regional Outlook, Growth Potential, Competitive Market Share & Forecast, 2025 – 2034

Therapeutic Nuclear Medicine Market Size

The global therapeutic nuclear medicine market generated revenues in 2024 and is expected to exhibit a decent CAGR from 2025 to 2034 due to the increasing incidence of cancer, continuing awareness of the efficacy of radiopharmaceutical therapies, and advances in targeted treatments. In 2024, as per the NIH gov. there were 2,001,140 new cancer cases diagnosed and 611,720 cancer deaths in the United States.  Therapeutic nuclear medicine therapy uses radioactive substances to target and destroy diseased tissue and is becoming a popular alternative to traditional drugs therapies due to its specificity and measurably effective, especially for UK and US patients with thyroid disease, lymphomas, prostate cancers and bone metastases.
 

Healthcare professionals and patients are recognizing the potential of therapeutic nuclear medicine to limit the amount of damage to healthy tissue and brain tissues and to lower the side effects of traditional conventional methods. Continuing improvements in imaging and radionuclide delivery systems are assisting the therapy outcomes and continue to make the demand for the products continue to rise. As global health data predicts a continuous increase in cancer cases, radionuclide therapy offers one option for an alternative or accompaniment to surgery, chemotherapy, or external beam radiation.
 

The growing awareness amongst clinicians and patients on the effectiveness of using radiopharmaceuticals to treat primary and metastatic tumors has increased uptake. However, radiopharmaceuticals only have a short half-life (the radio-iodine isotope used in RAI) so production and distribution need to be timed very carefully. Also, this requires a well-coordinated supply chain and a significant amount of investment into infrastructure. The rules and regulations about the handling of radioisotopes ( licensing, environmental impacts) and radiation can also afford barriers to use, hindering market growth.
 

Therapeutic Nuclear Medicine Market Trends

One of the most revolutionary trends in the therapeutic nuclear medicine market is the development of personalized and targeted radionuclide therapy. Advancements in molecular imaging have enabled the pairing of precise radioactive compounds to tumor receptors to develop treatment regimens specific to each patient. Peptide receptor radionuclide therapy (PRRT), for instance, is quickly finding a place in treating neuroendocrine tumors, with possible other indications. Besides this positive news, hybrid imaging capabilities such as PET/CT and SPECT/CT are another interesting advance in disease-specific therapeutic nuclear medicine approaches.
 

The development of alpha emitters like Actinium-225 spotlights another growing area of radionuclide therapy. They offer the potential for even greater therapeutic circumstances due to their higher linear energy transfer, resulting in more powerful localized tumor destruction and diminished side effects. At the same time, research is progressing in exploring additional medical conditions to expand the clinical applicability of existing isotopes including inflammatory diseases and cardiology.
 

Therapeutic Nuclear Medicine Market Analysis

The beta emitters segment held the largest market share in 2024 and will continue to lead through 2034. Beta-emitting isotopes such as Iodine-131, Lutetium-177, and Yttrium-90 are prevalent in cancer therapies for thyroid cancer, prostate cancer, liver cancer, and others, all of which have beta-emitting isotopes to treat this disease. Beta emitters create beta particles with sufficient penetration for tissue to treat tumors while minimizing the exposure to healthy cells immediately in the surrounding area.
 

Lutetium-177 has gained particular traction in the clinic as it provides the ability to combine diagnostic and therapeutic ability, which is referred to as "theranostics". Products such as Lutathera® (indicated for neuroendocrine tumors) have caused an accelerated acceptance in clinics for both patients and generality of use. In prostate cancer, Lu-177-PSMA therapy has shown great promise as a therapeutic alternative, which is specifically important in patients with advanced disease who are resistant to conventional treatment. Clinical studies have demonstrated the ability of beta emitters to improve progression-free survival and quality of life outcomes in patients which has increased uptake in academic and private clinics.
 

The therapeutic nuclear medicine market from ambulatory surgical centers segment made a noticeable contribution in 2024 driven by the decentralized and more cost-effective models of patient care. ASCs provide patients with a convenient option that allows for shorter hospital stays, and the ability to access a specialized treatment facility with minimum overheads of a larger hospital. ASCs have become more capable of delivering outpatient nuclear medicine procedures as overall radiopharmaceutical logistics and safety protocols have evolved.
 

Many radionuclide therapies, especially ones that utilize beta emitters like Lutetium-177 or Iodine-131, can now fall into day-based treatment regimens; freeing up tertiary care centers and increasing the volume of patients returning home. In addition, in many countries, recent policy changes have made access for ASCs to obtain radioactive materials licensing easier, therefore increasing the pool of available patients and decreasing the overall time from therapy initiation to delivery, especially in urban or semi-urban areas. Also, recent partnerships between diagnostic labs, pharmaceutical companies, and ASCs have allowed for better resource sharing, mostly in imaging equipment and trained personnel.
 

North America therapeutic nuclear medicine market is expected to maintain its position through 2034. The region benefits from a well-developed medical system with public and private investments for cancer treatment, a financially supportive reimbursement structure, and the support of the FDA's streamlining regulations. The U.S. is the largest market in the world, with significant nuclear medicine capacity, research funding, and rapid uptake of new radionuclide therapies.
 

Big pharma and biotechnology companies are located mostly in North America, such as Novartis, Cardinal Health, and GE HealthCare, advancing innovation. The FDA is setting out to shape the market and further stimulate therapeutics with its moves towards a streamlined approach to the regulation of targeted radiotherapies and targeted radiopharmaceuticals, including diagnostics.
 

The number of diagnosed cancers, including thyroid cancer, prostate cancer, and neuroendocrine tumors increased for targeted radiotherapy, public awareness has led to more physicians referring patients and the resulting higher treatment levels. Canada is capitalizing on strategic collaborations between academic institutions and isotope producers to expand the reach of therapeutic nuclear medicine in Canada too.  Alongside existing clinical trials, the development of government funding for isotope production and new paradigms of cutting-edge hybrid imaging technologies.
 

Therapeutic Nuclear Medicine Market Share

The therapeutic nuclear medicine industry players include:

• Progenics Pharmaceuticals (Lantheus Holdings)
• Eckert & Ziegler
• Jubilant Pharma
• Advanced Accelerator Applications (Novartis)
   

To solidify their positions in the therapeutic nuclear medicine market, major corporations focus on exploring strategic partnerships, mergers, and acquisitions resulting in partnerships that would bolster their radiopharmaceutical pipelines and supply chain. Major corporations are investing heavily in in-house isotope production facilities, especially focusing on Lutetium-177 and Actinium-225 which enable companies to establish their supply chain and mitigate risks of an external supplier.
 

Companies are increasing capital investments in clinical trials to expand indications of current therapies, which can lead to greater FDA and EMA approvals. Companies are developing collaborations with hospitals and ambulatory centers and are providing the proper training and infrastructure support to conduct the safe and effective delivery of treatment.
 

Therapeutic Nuclear Medicine Industry News

• In February 2025, Charles J. Ejiofor stated that nuclear medicine had ushered in a new era for Nigeria’s healthcare, offering advanced tools for diagnosing and treating critical illnesses like cancer. With radioactive substances improving diagnostics and therapies, this shift was vital for enhancing healthcare and quality of life in Nigeria.
   
• In April 2025, Actinium Pharmaceuticals launched ATNM-400, describing it as a novel radiotherapy for prostate cancer that did not target prostate-specific membrane antigen (PSMA). This therapy used the actinium-225 radioisotope to offer a new approach beyond traditional PSMA-focused treatments.